Table 3. Immediate research priorities.

Disease	Research Goal	Feasibility (0–10a: 0, Impossible; 10, Inevitable)	Impact if Achieved (0–10a: 0, None; 10, Massive)
Lymphatic filariasis	Development of antigen tests to usable/reliable format	9	8 if ≤USD 0.50
	Development and validation of tests (e.g., IgG4-subclass antibody detection tests using recombinant Bm14, BmR1, WbSXP, and W. bancrofti-specific antigens [20] or PCR-based detection of parasite DNA in homogenised mosquitoes [21]) useful for post-elimination surveillance, with accompanying standardised survey methodologies	9	8 if ≤USD 0.50
Trachoma	Development of a test for ocular C. trachomatis infection [22] able to maintain specificity at high temperatures and low humidity [23]	9	8 if ≤USD 0.50
	Development of eye/nose swab-, saliva-, or blood-based anti-C. trachomatis antibody test and exploration of the impact of successful trachoma control on antibody profiles in endemic populations	3	5
	Development and validation of a school-based survey protocol (need threshold minimum school attendance)	7	8
Schistosomiasis	Development of antigen [24] or antibody [25] isotype combination(s) useful in high and low transmission intensity environments, able to distinguish current from past infection	8	9
	Development of antigen or antibody isotype combination(s) to distinguish between different species	8	4
	Development of serum markers of morbidity	6	8
Soil-transmitted helminthiases	Development of reliable blood- or urine-based assays for detection of current infection	4	9
	Development of serum markers of morbidity	6	8
Onchocerciasis	Development of a quantitative antigen test for use in endemic areas in Africa and validation of Ov16 antibody test for demonstrating interruption of transmission in Africa	5	8
	Development of a test for loaiasis	5	9

^aDetermined by expert consensus.